Skip to main content

Table 2 Clinical characteristics of patients with COVID-19 in the training cohort

From: Nomogram to identify severe coronavirus disease 2019 (COVID-19) based on initial clinical and CT characteristics: a multi-center study

Clinical characteristics Mild group(n = 102) Severe group(n = 50) t / Z / χ2 value P value
Sex    0.691 0.406
 Male 56 (54.9) 31 (62.0)   
 Female 46 (45.1) 19 (38.0)   
Age 40.70 ± 17.21 56.18 ± 14.52 −5.476 < 0.001
Hypertension    0.046 0.830
 Yes 13 (12.7) 7 (14.0)   
 No 89 (87.3) 43 (86.0)   
Diabetes    12.59 0.001
 Yes 7 (6.9) 14 (28.0)   
 No 95 (93.1) 36 (72.0)   
Coronary heart disease    5.197 0.023
 Yes 1 (1.0) 4 (8.0)   
 No 101 (99.0) 46 (92.0)   
COPD    0.545 0.461
 Yes 2 (2.0) 2 (4.0)   
 No 100 (98.0) 48 (96.0)   
Leucocyte counts (×109 /L) 5.11 (3.94–6.15) 6.31 (4.44–8.36) −3.071 0.002
Neutrophil counts (× 109 /L) 3.00 (1.94–3.89) 4.23 (3.00–6.57) −4.471 < 0.001
Lymphocyte counts (×109 /L) 1.33 (1.00–1.82) 0.91 (0.65–1.29) −3.798 < 0.001
Platelet (×109 /L) 178 (147–211) 204 (150–270) −2.469 0.014
NLR 2.30 (1.41–3.22) 4.63 (2.67–7.34) −5.749 < 0.001
PLR 132.64 (97.71–169.21) 219.37 (157.54–319.70) −5.757 < 0.001
CRP (mg/L) 6.70 (0.90–17.60) 34.55 (7.48–70.52) −5.419 < 0.001
Days from illness onset to admission 4 (2.0–6.0) 5 (3.0–7.0) −1.259 0.208
  1. Note: COPD chronic obstructive pulmonary disease, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CRP C-reactive protein
  2. Data are numbers of patients, with percentages in parentheses